In a separate multivariable analysis, outcomes of only patients undergoing non-ablative allogeneic transplants were considered. (Table 5 ) The most important predictors of survival, PFS and In order to discern any association between chronic GVHD and disease progression, we examined this association and its effects on PFS, in a time-dependent fashion among recipients of nonablative transplants. We found only a weak association between patients with clinical extensive chronic GVHD and reduced rates of progression or relapse HR ¼ 0.74 (0.4 --1.3), P ¼ 0.32. This resulted in no net benefit on PFS HR ¼ 0.89 (0.5 --1.5), P ¼ 0.65.